MILAN, July 4, 2016 /PRNewswire/ --
Marco Filippini, Mundipharma Italy General Manager and France & Southern Europe Regional Director, has been appointed Vice Coordinator of the Italian Biosimilars Group (IBG), a member of Assogenerici, the Italian Association of Generic and Biosimilar Drugs Producers.
This appointment confirms Mundipharma's commitment to the biosimilar sector, following its 2015 launch of Remsima® (infliximab), the first biosimilar monoclonal antibody licenced by the European Medicines Agency (EMA) for the treatment of immune-mediated inflammatory diseases.
Together with Marco Filippini, Stefano Collatina, Hospital Products Business Unit Director of Baxter, has also been appointed Vice Coordinator by IBG. The two new designations come from IBG's need to adopt a new governance model, able to take on present and future challenges in the biosimilar industry, increasingly important within the pharmaceutical sector.
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. The Mundipharma network has a presence in 51 countries with more than 7,800 employees across the world. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide.
For further information please visit: http://www.mundipharma.com